Astorga R, Cantero O, Contreras D, del Río-Martín A, Labarta-Beceiro V, Gutiérrez-Elvírez A, Lima-López M A, López-Saura P
General Calixto García Hospital, Havana, Cuba.
Arch Esp Urol. 2000 Sep;53(7):665-71.
To evaluate interferon alpha-2b (IFN) in the treatment of Peyronie's disease (PD) since IFN exerts antifibrotic action through collagen synthesis inhibition and fibrolysis stimulation.
The study comprised 34 patients, aged 31 to 63, with clinical and ultrasonographic (US) diagnosis of PD, who gave their consent to enter the study. They had the disease for 10.1 +/- 5.6 (2-22) months. Ten million IU of IFN were injected intralesionally, twice weekly for 14 weeks or less if there was complete remission. Clinical evaluation included penis angle at erection, sexual dysfunction (pain, possibility of intercourse) and palpable plaque. Plaque size was evaluated by US. Systemic and local adverse reactions, and anti-IFN antibodies were monitored as well.
Sexual dysfunction disappeared in 19/24 (79.2%) patients with this disorder, palpable lesions in 21/34 (62%), angle at erection in 15/32 (47%), and pain in 16/17 (94%). Complete clinical response was achieved in 16/34 patients (47%). Ultrasonographic response rate was 88%, (53% complete). Plaque size decreased from 56.7 +/- 42.9 (median: 35.4) before treatment to 12.7 +/- 22.6 mm2 (median: 0) (p < 0.00001; Wilcoxon's paired test). Clinical and US responses correlated. No patient showed progression. Eight of 9 patients in whom other treatments had failed responded to IFN therapy (5 complete). The main systemic adverse reaction in most patients (mild or moderate) was the flu-like syndrome expected for IFN. Local reactions, more related to the administration procedure than to IFN itself, were small hematoma (10 patients), edema (3), cysts that were excised surgically (2), and venous leak (1). No patient developed anti-IFN antibodies.
IFN treatment can be a suitable option for the management of PD. The results appear to be better than those achieved with other procedures. Further work should include comparative studies, long-term follow-up of treated patients, and alternative ways of administration.
鉴于干扰素α-2b(IFN)可通过抑制胶原蛋白合成和刺激纤维蛋白溶解发挥抗纤维化作用,评估其对佩罗尼氏病(PD)的治疗效果。
该研究纳入了34例年龄在31至63岁之间、经临床和超声(US)诊断为PD且同意参与研究的患者。他们患病时间为10.1±5.6(2 - 22)个月。将1000万国际单位的IFN进行病灶内注射,每周两次,共14周,若完全缓解则疗程可缩短。临床评估包括勃起时阴茎角度、性功能(疼痛、性交可能性)以及可触及的斑块。通过超声评估斑块大小。同时监测全身和局部不良反应以及抗IFN抗体。
24例患有性功能障碍的患者中,19例(79.2%)性功能障碍消失;34例中有21例(62%)可触及病变消失;32例中有15例(47%)勃起角度改善;17例中有16例(94%)疼痛缓解。34例患者中有16例(47%)实现了完全临床缓解。超声反应率为88%(53%为完全缓解)。斑块大小从治疗前的56.7±42.9(中位数:35.4)减小至12.7±22.6平方毫米(中位数:0)(p < 0.00001;Wilcoxon配对检验)。临床和超声反应相关。无患者病情进展。9例其他治疗失败的患者中有8例对IFN治疗有反应(5例完全缓解)。大多数患者(轻度或中度)的主要全身不良反应是IFN预期会出现的流感样综合征。局部反应更多与给药操作有关而非IFN本身,包括小血肿(10例患者)、水肿(3例)、经手术切除的囊肿(2例)以及静脉漏(1例)。无患者产生抗IFN抗体。
IFN治疗可能是PD治疗的一个合适选择。其结果似乎优于其他治疗方法。进一步的工作应包括对比研究、对治疗患者的长期随访以及其他给药方式。